Emerging therapies for autoimmune myasthenia gravis: Towards treatment without corticosteroids

[1]  K. Charissé,et al.  Investigational RNAi Therapeutic Targeting C5 Is Efficacious in Pre-clinical Models of Myasthenia Gravis , 2019, Molecular therapy. Methods & clinical development.

[2]  Z. Siddiqi,et al.  Therapies Directed Against B-Cells and Downstream Effectors in Generalized Autoimmune Myasthenia Gravis: Current Status , 2019, Drugs.

[3]  G. Rimmelzwaan,et al.  A prospective, double-blind, randomized, placebo-controlled study on the efficacy and safety of influenza vaccination in myasthenia gravis. , 2019, Vaccine.

[4]  K. McKeage.  Ravulizumab: First Global Approval , 2019, Drugs.

[5]  R. Montgomery,et al.  IdeS (Imlifidase): A Novel Agent That Cleaves Human IgG and Permits Successful Kidney Transplantation Across High-strength Donor-specific Antibody , 2018, Annals of surgery.

[6]  R. Ober,et al.  Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans , 2018, The Journal of clinical investigation.

[7]  L. Björck,et al.  Safety, immunogenicity, pharmacokinetics, and efficacy of degradation of anti‐HLA antibodies by IdeS (imlifidase) in chronic kidney disease patients , 2018, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[8]  D. Sanders,et al.  Randomized study of adjunctive belimumab in participants with generalized myasthenia gravis , 2018, Neurology.

[9]  M. Benatar,et al.  RA101495, A Subcutaneously Administered Peptide Inhibitor of Complement Component 5 (C5) for the Treatment of Generalized Myasthenia Gravis (gMG): Phase 1 Results and Phase 2 Design (S31.006) , 2018 .

[10]  I. Sunwoo,et al.  3,4-Diaminopyridine for the treatment of myasthenia gravis with electrophysiological patterns of Lambert-Eaton myasthenic syndrome , 2018, Journal of Clinical Neuroscience.

[11]  N. Gilhus,et al.  Myasthenia gravis and infectious disease , 2018, Journal of Neurology.

[12]  V. Damato,et al.  Myasthenia gravis with antibodies to MuSK: an update , 2018, Annals of the New York Academy of Sciences.

[13]  Jacqueline A Palace,et al.  Therapeutic strategies for congenital myasthenic syndromes , 2018, Annals of the New York Academy of Sciences.

[14]  G. L. Masson,et al.  Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. , 2017, The Lancet. Neurology.

[15]  U. Dalgas,et al.  Exercise in myasthenia gravis: A feasibility study of aerobic and resistance training , 2017, Muscle & nerve.

[16]  M. Benatar,et al.  Rituximab as treatment for anti-MuSK myasthenia gravis , 2017, Neurology.

[17]  M. Emtner,et al.  Physical exercise in myasthenia gravis is safe and improves neuromuscular parameters and physical performance‐based measures: A pilot study , 2017, Muscle & nerve.

[18]  R. Tandan,et al.  Rituximab treatment of myasthenia gravis: A systematic review , 2017, Muscle & nerve.

[19]  R. Gold,et al.  Bortezomib in severe MuSK-antibody positive myasthenia gravis: first clinical experience , 2017, Therapeutic advances in neurological disorders.

[20]  A. Schwarting,et al.  Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty‐Two–Week Randomized, Double‐Blind, Placebo‐Controlled Study , 2017, Arthritis & rheumatology.

[21]  C. Vrinten,et al.  Ephedrine treatment for autoimmune myasthenia gravis , 2017, Neuromuscular Disorders.

[22]  G. Cutter,et al.  Randomized trial of thymectomy in myasthenia gravis. , 2016, Journal of thoracic disease.

[23]  Yuebing Li,et al.  Maintenance immunosuppression in myasthenia gravis , 2016, Journal of the Neurological Sciences.

[24]  Sreenivasa Rao Sudulagunta,et al.  Refractory myasthenia gravis – clinical profile, comorbidities and response to rituximab , 2016, German medical science : GMS e-journal.

[25]  A. Marx,et al.  Randomized trial of thymectomy in myasthenia gravis. , 2016, Journal of thoracic disease.

[26]  M. Benatar,et al.  International consensus guidance for management of myasthenia gravis , 2016, Neurology.

[27]  M. Benatar,et al.  A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis , 2016, Neurology.

[28]  V. Damato,et al.  3,4-Diaminopyridine may improve myasthenia gravis with MuSK antibodies , 2016, Neurology.

[29]  M. Benatar,et al.  Efficacy of prednisone for the treatment of ocular myasthenia (EPITOME): A randomized, controlled trial , 2016, Muscle & nerve.

[30]  Nils Erik Gilhus,et al.  Myasthenia gravis: subgroup classification and therapeutic strategies , 2015, The Lancet Neurology.

[31]  Jacqueline A Palace,et al.  Salbutamol and ephedrine in the treatment of severe AChR deficiency syndromes , 2015, Neurology.

[32]  M. Farrugia,et al.  Myasthenia gravis: Association of British Neurologists’ management guidelines , 2015, Practical Neurology.

[33]  P. Narayanaswami,et al.  Two steps forward, one step back: Mycophenolate mofetil treatment for myasthenia gravis in the united states , 2015, Muscle & nerve.

[34]  H. Lochmüller,et al.  Salbutamol therapy in congenital myasthenic syndrome due to DOK7 mutation , 2013, Journal of the Neurological Sciences.

[35]  J. Goldstein,et al.  Clinical Characteristics of Refractory Myasthenia Gravis Patients , 2013, The Yale journal of biology and medicine.

[36]  F. Zimprich,et al.  The effect of early prednisolone treatment on the generalization rate in ocular myasthenia gravis , 2013, European journal of neurology.

[37]  J. Verschuuren,et al.  Long-lasting treatment effect of rituximab in MuSK myasthenia , 2012, Neurology.

[38]  R. Mantegazza,et al.  Current and emerging therapies for the treatment of myasthenia gravis , 2011, Neuropsychiatric disease and treatment.

[39]  D. Sanders,et al.  Immunosuppressive therapies in myasthenia gravis , 2010, Autoimmunity.

[40]  C. Cardwell,et al.  A systematic review of population based epidemiological studies in Myasthenia Gravis , 2010, BMC neurology.

[41]  J. Palace,et al.  Ephedrine treatment in congenital myasthenic syndrome due to mutations in DOK7 , 2010, Neurology.

[42]  D. Richman,et al.  An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis , 2008, Neurology.

[43]  D. Sanders,et al.  Lessons from Two Trials of Mycophenolate Mofetil in Myasthenia Gravis , 2008, Annals of the New York Academy of Sciences.

[44]  B. Kim,et al.  Clinical predictors of steroid-induced exacerbation in myasthenia gravis , 2006, Journal of Clinical Neuroscience.

[45]  Charles George,et al.  Sleep apnea in patients with myasthenia gravis , 2006, Neurology.

[46]  T. MacDonald,et al.  Taking Glucocorticoids by Prescription Is Associated with Subsequent Cardiovascular Disease , 2004, Annals of Internal Medicine.

[47]  P. Emery,et al.  Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. , 2004, The New England journal of medicine.

[48]  J. King,et al.  Immunotherapy of Ocular Myasthenia Gravis Reduces Conversion to Generalized Myasthenia Gravis , 2003, Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society.

[49]  D. Sanders,et al.  Mycophenolate mofetil for myasthenia gravis , 2003, Neurology.

[50]  M. Kupersmith,et al.  Development of generalized disease at 2 years in patients with ocular myasthenia gravis. , 2003, Archives of neurology.

[51]  D. Sanders,et al.  Mycophenolate mofetil for myasthenia gravis: An open-label pilot study , 2001, Neurology.

[52]  John Newsom-Davis,et al.  A randomized double‐blind trial of prednisolone alone or with azathioprine in myasthenia gravis , 1998, Neurology.

[53]  Sollinger Hw.  Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. , 1995 .

[54]  R. Tindall,et al.  A Clinical Therapeutic Trial of Cyclosporine in Myasthenia Gravis a , 1993, Annals of the New York Academy of Sciences.

[55]  J. Kremer,et al.  The safety and efficacy of the use of methotrexate in long-term therapy for rheumatoid arthritis. , 1986, Arthritis and rheumatism.

[56]  H. Oosterhuis.  The ocular signs and symptoms of myasthenia gravis , 1982, Documenta Ophthalmologica.

[57]  J. Lindstrom,et al.  PATTERNS OF ACETYLCHOLINE RECEPTOR ANTIBODY FLUCTUATION IN MY ASTHENIA GRAVIS * , 1981, Annals of the New York Academy of Sciences.

[58]  G. Genkins,et al.  Studies in myasthenia gravis: review of a twenty-year experience in over 1200 patients. , 1971, The Mount Sinai journal of medicine, New York.

[59]  Nils E Gilhus.  Myasthenia Gravis. , 2016, The New England journal of medicine.

[60]  I. Rosén,et al.  Improvement in Neuromuscular transmission in Myasthenia Gravis by 3,4-Diaminopyridine , 2004, European archives of psychiatry and neurological sciences.

[61]  H. Sollinger.  Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. , 1995, Transplantation.

[62]  I. Illa,et al.  [Predictive factors of the response to treatment of myasthenia gravis with prednisone]. , 1990, Neurologia.